As part of a previously announced restructuring effort, Natick, MA-based Boston Scientific (NYSE: [[ticker:BSX]]) has agreed to sell two of its businesses to private equity firm Avista Capital Partners for $425 million in cash. With this deal, which is expected to close in the first quarter of next year, “We now have under agreement the divestitures of all five non-strategic businesses we had previously identified for sale,” said Boston Scientific president and CEO Jim Tobin in a statement.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
